| Clinical data | |
|---|---|
| Other names | 4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H17N3O2 |
| Molar mass | 295.342 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
GYKI 52895 is a drug which is a 2,3-benzodiazepine derivative that also shares the3,4-methylenedioxyamphetaminepharmacophore. Unlike other similar drugs, GYKI 52895 is a selectivedopamine reuptake inhibitor (DRI),[1][2] which appears to have an atypical mode of action compared to other DRIs.[3] Its DRI activity is shared by numerous addictive drugs includingamphetamine and its derivatives (e.g.dextromethamphetamine),cocaine, andmethylphenidate and its derivatives (e.g.ethylphenidate). However, dopaminergic drugs are also prone to producingemetic effects such as in the case ofapomorphine.
Egis Pharmaceuticals began clinical development of the drug in 1997 formajor depressive disorder andParkinson's disease, but it was discontinued in 2001.[4]
| 1,4-Benzodiazepines |
|
|---|---|
| 1,5-Benzodiazepines | |
| 2,3-Benzodiazepines* | |
| Triazolobenzodiazepines | |
| Imidazobenzodiazepines | |
| Oxazolobenzodiazepines | |
| Thienodiazepines | |
| Thienotriazolodiazepines | |
| Thienobenzodiazepines* | |
| Pyridodiazepines | |
| Pyridotriazolodiazepines | |
| Pyrazolodiazepines | |
| Pyrrolodiazepines | |
| Tetrahydroisoquinobenzodiazepines | |
| Pyrrolobenzodiazepines* | |
| Benzodiazepine prodrugs | |
* atypical activity profile (notGABAA receptor ligands) | |
| Phenethylamines |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphetamines |
| ||||||||||||||||
| Phentermines |
| ||||||||||||||||
| Cathinones | |||||||||||||||||
| Phenylisobutylamines (and further-extended) | |||||||||||||||||
| Catecholamines (and close relatives) |
| ||||||||||||||||
| Cyclized phenethylamines |
| ||||||||||||||||
| Related compounds |
| ||||||||||||||||